Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2024 Jun 1.

Published in final edited form as: Leukemia. 2023 Apr 19;37(6):1194–1203. doi: 10.1038/s41375-023-01900-5

Table 1.

PK parameters of dasatinib and ponatinib in orally-dosed mice

Dasatinib		Ponatinib
	Median (5^th-95^th percentile)		Median (5^th-95^th percentile)
AUC_0–24hrs 20 mg (ng hr/mL)	495.21 (253.15–1170.58)	AUC_0–24hrs 15 mg (ng hr/mL)	1524.53 (1363.64–1718.81)
AUC_0–24hrs 40 mg (ng hr/mL)	1940.07 (907.47–4024.05)	AUC_0–24hrs 30 mg (ng hr/mL)	2996.56 (2707.46–3351.17)
AUC_0-infinity 20 mg (ng hr/mL)	499.51 (253.33–1173.71)	AUC_0-infinity 15 mg (ng hr/mL)	1533.22 (1367.25–1727.10)
AUC_0-infinity 40 mg (ng hr/mL)	1952.88 (908.72–4027.31)	AUC_0-infinity 30 mg (ng hr/mL)	3010.21 (2716.52–3365.01)
C_max 20 mg (ng/mL)	102.00 (37.81–230.62)	C_max 15 mg (ng/mL)	181.36 (153.95–210.12)
C_max 40 mg (ng/mL)	366.36 (166.52–847.16)	C_max 30 mg (ng/mL)	355.84 (308.83–412.35)
T_max 20 mg (hrs)	1.17 (0.83–1.42)	T_max 15 mg (hrs)	3.04 (2.54–3.58)
T_max 40 mg (hrs)	1.17 (0.92–1.42)	T_max 30 mg (hrs)	3.08 (2.63–3.58)
t_1/2 20 mg (hrs)	0.35 (0.27–0.45)	t_1/2 15 mg (hrs)	1.92 (1.32–2.57)
t_1/2 40 mg (hrs)	0.34 (0.27–0.34)	t_1/2 30 mg (hrs)	1.92 (1.42–2.51)
CL/f 20 mg (mL/hr/kg)	667.41 (284.01–1315.89)	CL/f 15 mg (mL/hr/kg)	9.78 (8.69–10.97)
CL/f 40 mg (mL/hr/kg)	341.38 (165.82–733.74)	CL/f 30 mg (mL/hr/kg)	9.97 (8.92–11.04)

AUC, area under the curve; CL/f, apparent clearance; PK, pharmacokinetic.